On Biosimilar Names, FDA Charts Middle Course
The U.S. Food and Drug Administration's draft guidance on Thursday regarding naming of biosimilars wasn't a clear-cut victory for either brand-name or generic-biologic makers, according to experts who say that a...To view the full article, register now.
Already a subscriber? Click here to view full article